Switch From 2mg Aflibercept to 8mg Aflibercept in Patients With Neovascular Age-related Macular Degeneration

Inclusion Criteria: * Patients, who received prior intravitreal anti-VEGF-treatment for nAMD with Aflibercept 2mg. A minimum of four injections of Aflibercept 2mg is required. Therefore 16-24 weeks prior treatment with anti-VEGF is required in line with an interval of 4-8 weeks. * Short treatment intervals of 4 or 8 weeks * nAMD * Age 21 or older * Written informed consent Exclusion Criteria: * Chronic treatment with Bevacizumab or Faricimab * Extensive macular fibrosis * Diabetic retinopathy * Other retinal pathologies (e.g. retinal vein occlusion) * Dense media opacities (cataract, corneal scars) * Vitreous hemorrhage * Ocular or periocular infections * Active intraocular inflammation * Hypersensitivity to the active substance or to any of the excipients * Prior Aflibercept 8mg treatment * Pregnancy (for women in reproductive age a pregnancy test will be performed)